#United States #San Francisco #Securities Class Action #GeneDx #Fabric Genomics

GeneDx Holdings Faces Securities Class Action Due to Stock Drop

GeneDx Holdings (NASDAQ: WGS) is currently embroiled in a securities class action lawsuit after a staggering drop of nearly 49% in its stock price. On May 5, 2026, the company reported disappointing Q1 earnings that led to a significant decline, closing at $33.42 per share. This financial turmoil has raised concerns among investors, leading to the lawsuit aimed at seeking damages for those who purchased shares from April 16, 2025, to May 4, 2026.

The class action has been initiated by the national shareholder rights law firm Hagens Berman, which is investigating whether GeneDx may have violated federal securities laws. The firm highlights the necessity for affected investors to reach out promptly to understand their rights and options. The complaint alleges GeneDx made several misleading statements regarding the importance of its recent acquisition of Fabric Genomics and the expected revenue generation from it.

Business Overview and Growth Promises

GeneDx conducts clinical diagnostic tests primarily focusing on rare and ultra-rare diseases, boasting robust technology in whole genome and whole exome sequencing. The bulk of their revenue relies on genetic tests, and they have consistently communicated a strong growth narrative to their investors. For 2025, GeneDx indicated an average reimbursement rate (ARR) of $3750 for their services, a number they suggested would remain stable in 2026. The management had even projected growth of 33% to 35% for genome and exome testing in 2026, promising a positive outlook.

In an effort to diversify and expand its business model, GeneDx acquired Fabric Genomics for around $33.2 million on May 5, 2025. The company claimed this acquisition would not only enhance its revenue potential but also transform it into a dynamic platform allowing higher profit margins and recurring revenue streams.

The Shift in Narrative

However, the narrative took a drastic turn on May 4, 2026, when GeneDx reported Q1 results that yielded significantly greater net losses compared to the same period in the previous year. Most alarmingly, the acquisition of Fabric Genomics contributed a $2.5 million revenue miss, resulting in impairment charges valued at $31.2 million — a staggering 94% of what was initially paid for the acquisition. On top of that, the ARR fell short by about $2000, contradicting previous assurances by management about its stability.

The news of a dramatic drop in expected revenue growth crushed investor confidence and caused a ripple effect, leading to a drastic 12% reduction in 2026 revenue guidance from GeneDx. As these revelations came to light, Hagens Berman raised questions regarding whether GeneDx knowingly misled investors about the acquisition's importance and the subsequent drop in their projected growth.

Conclusion and Call to Action

As the investigation unfolds, Hagens Berman urges any investors who incurred losses around the time of the earnings report or suspect they possess non-public information about GeneDx's practices to come forward. The potential ramifications of this class action remain uncertain yet significant, as it could affect the company’s financial standing and its ongoing viability in the highly competitive diagnostics market.

For those wishing to learn more about GeneDx's securities class action or who have pertinent information, further resources and guidance can be sought through Hagens Berman, facilitating the pursuit of justice for shareholders affected by this corporate turmoil.